Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

Brain

Volumn 131, Issue 6, 2008, Pages 1630-1645

  Ikonomovic, Milos D ^a   Klunk, William E ^a   Abrahamson, Eric E ^a   Mathis, Chester A ^a   Price, Julie C ^a   Tsopelas, Nicholas D ^a   Lopresti, Brian J ^a   Ziolko, Scott ^a   Bi, Wenzhu ^a   Paljug, William R ^a   Debnath, Manik L ^a   Hope, Caroline E ^a   Isanski, Barbara A ^a   Hamilton, Ronald L ^a   DeKosky, Steven T ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Department of Neurology ^*  (United States)

Author keywords

Amyloid imaging; PET imaging; PiB; Pittsburgh Compound B; Plaques

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; PITTSBURGH COMPOUND B; TAU PROTEIN; TRACER;

ALZHEIMER DISEASE; ARTICLE; BETA SHEET; BRAIN HOMOGENATE; BRAIN TISSUE; CADAVER; CAUDATE NUCLEUS; DRUG BINDING; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; HUMAN; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; NEUROFIBRILLARY TANGLE; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; TEMPORAL CORTEX;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANILINE COMPOUNDS; AUTOPSY; BRAIN; CARBON RADIOISOTOPES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEUROFIBRILLARY TANGLES; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; SENILE PLAQUES; TAU PROTEINS; THIAZOLES;

EID: 43849083580     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awn016     Document Type: Article

References (65)

1. Consensus report of the Working Group on "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998; 19: 109-16.
2. Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, et al. Molecular imaging with PiB confirmed at autopsy: a case report. Arch Neurol 2007; 64: 431-4.
3. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropath 1991a; 82: 239-59.
4. Braak H, Braak E. Neuropathological staging of Alzheimer's disease. Acta Neuropath 1991b; 82: 239-59.
5. DeKosky ST, Abrahamson EE, Ciallella JR, Paljug WR, Wisniewski SR, Clark RSB, et al. Association of increased cortical soluble abeta42 levels with diffuse plaques after severe brain injury in humans. Arch Neurol 2007; 64: 541-44.
6. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129: 2856-66.
7. Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 2007; 27: 10365-71.
8. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2007 [Epub ahead of print] (doi: 10.1016/j.neurobiolaging.2007. 03.029).
9. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, et al. Mild cognitive impairment. Lancet 2006; 367: 1262-70.
10. Growdon JH. Biomarkers of Alzheimer disease. Arch Neurol 1999; 56: 281-3.
11. Grundke-Iqbal I, Iqbal K, George L, Tung YC, Kim KS, Wisniewski HM. Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease. Proc Natl Acad Sci USA 1989; 86: 2853-57.
12. Guntern R, Bouras C, Hof PR, Vallet PG. An improved thioflavine-S method for staining neurofibrillary tangles and senile plaques in Alzheimer's disease. Experientia 1992; 48: 8-10.
13. Harigaya Y, Saido TC, Eckman CB, Prada CM, Shoji M, Younkin SG. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochem Biophys Res Commun 2000; 276: 422-27.
14. Hyman BT, Tanzi RE, Marzloff K, Barbour R, Schenk D. Kunitz protease inhibitor-containing amyloid beta protein precursor immunoreactivity in Alzheimer's disease. J Neuropathol Exp Neurol 1992; 51: 76-83.
15. Hyman BT, Van Hoesen GW, Beyreuther K, Masters CL. A4 amyloid protein immunoreactivity is present in Alzheimer's disease neurofibrillary tangles. Neurosci Lett 1989; 101: 352-55.
16. Ikonomovic MD, Abrahamson EE, Isanski BA, Debnath ML, Mathis CA, DeKosky ST, et al. X-34, a histofluorescent marker of abnormal protein aggregates with amyloid structure, in neuropathological studies of preclinical and clinical Alzheimer's disease. Methods Enzymol 2006; 412: 123-44.
17. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43). Neuron 1994; 13: 45-53.
18. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007; 62: 229-34.
19. Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LS. Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 2001; 414: 643-8.
20. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007; 68: 1603-06.
21. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985; 42: 1097-105.
22. Kim K, Wen G, Bancher C, Chen CMJ, Sapienza VJ, Hong H, et al. Detection and quantification of β-peptide with two monoclonal antibodies. Neurosci Res Commun 1990; 7: 113-22.
23. Kitamoto T, Ogomori K, Tateishi J, Prusiner SB. Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab Invest 1987; 57: 230-6.
24. Klunk WE. Biological markers of Alzheimer's disease. Neurobiol Aging 1998; 19: 145-47.
25. Klunk W, Engler H, Nordberg A, Bacskai BJ, Wang Y, Price JC, et al. Imaging the pathology of Alzheimer's disease: amyloid imaging with positron emission tomography. Neuroimaging Clin N Am 2003a; 13: 781-9.
26. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-19.
27. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 2005; 25: 10598-606.
28. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Mathis CA. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 2001; 69: 1471-84.
29. Klunk W, Yanming W, Huang G-F, Debnath ML, Holt DP, Shao L, et al. The binding of BTA-1 to post-mortem brain homogenates is dominated by amyloid component. J Neurosci 2003b; 23: 2086-92.
30. Lalowski M, Golabek A, Lemere CA, Selkoe DJ, Wisniewski HM, Beavis RC, et al. The "nonamyloidogenic" p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid. J Biol Chem 1996; 271: 33623-31.
31. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4: 153-58.
32. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 2007; 130: 2607-15.
33. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834-40.
34. Lopez OL, Becker JT, Klunk W, Saxton J, Hamilton RL, Kaufer DI, et al. Research evaluation and diagnosis of possible Alzheimer's disease over the last two decades: II. Neurology 2000a; 55: 1863-69.
35. Lopez OL, Becker JT, Klunk W, Saxton J, Hamilton RL, Kaufer DI, et al. Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I. Neurology 2000b; 55: 1854-62.
36. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005; 46: 1959-72.
37. Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T, et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci 2007; 27: 10957-968.
38. Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J 1985; 4: 2757-63.
39. Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch MP, Hyman BT, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 2002; 12: 295-98.
40. Mathis CA, Klunk WE, Price JC, DeKosky ST. Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch Neurol 2005; 62: 196-200.
41. Mathis C, Wang Y, Holt D, Huang G-F, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-aryl benzothiazoles as amyloid imaging agents. J Med Chem 2003; 46: 2740-55.
42. Mathis C, Wang Y, Klunk W. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharma Design 2004; 10: 1469-92.
43. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med 1998; 338: 506-11.
44. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44.
45. Meltzer CC, Kinahan PE, Greer PJ, Nichols TE, Comtat C, Cantwell MN, et al. Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med 1999; 40: 2053-65.
46. Mena R, Edwards PC, Harrington CR, Mukaetova-Ladinska EB, Wischik CM. Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease. Acta Neuropathol (Berl) 1996; 91: 633-41.
47. Mena R, Edwards P, Perez-Olvera O, Wischik CM. Monitoring pathological assembly of tau and beta-amyloid proteins in Alzheimer's disease. Acta Neuropathol 1995; 89: 50-6.
48. Mercken M, Vandermeeren M, Lubke U, Six J, Boons J, Van de Voorde A, et al. Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes. Acta Neuropathol 1992; 84: 265-72.
49. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984; 15: 217-27.
50. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-86.
51. Morris JC, Kimberly A, Quaid K, Holtzman DM, Kantarci K, Kaye J, et al. Role of biomarkers in studies of presymptomatic Alzheimer's disease. Alzheimer Dem 2005; 1: 145.
52. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, et al. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 2000; 283: 1571-77.
53. Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 2006; 65: 1040-48.
54. Pearl GS. Diagnosis of Alzheimer's disease in a community hospital-based brain bank program. South Med J 1997; 90: 720-22.
55. Perry G, Richey PL, Siedlak SL, Smith MA, Mulvihill P, Dewitt DA, et al. Immunocytochemical evidence that the beta-protein precursor is an integral component of neurofibrillary tangles of Alzheimers Disease. Am J Pathol 1993; 143: 1586-93.
56. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005; 25: 1528-47.
57. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-25.
58. Russo C, Violani E, Salis S, Venezia V, Dolcini V, Damonte G, et al. Pyroglutamate-modified amyloid beta-peptides-AbetaN3(pE)-strongly affect cultured neuron and astrocyte survival. J Neurochem 2002; 82: 1480-89.
59. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006; 355: 2652-63.
60. Spillantini MG, Goedert M, Jakes R, Klug A. Topographical relationship between beta-amyloid and tau protein epitopes in tangle-bearing cells in Alzheimer disease. Proc Natl Acad Sci USA 1990; 87: 3952-56.
61. Tabaton M, Cammarata S, Mancardi G, Manetto V, Autilio-Gambetti L, Perry G, et al. Ultrastructural localization of beta-amyloid, tau, and ubiquitin epitopes in extracellular neurofibrillary tangles. Proc Natl Acad Sci USA 1991; 88: 2098-102.
62. Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 2006; 20: 6-15.
63. Thies E, Mandelkow EM. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J Neurosci 2007; 27: 2896-907.
64. Verga L, Frangione B, Tagliavini F, Giaccone G, Migheli A, Bugiani O. Alzheimer patients and Down patients: cerebral preamyloid deposits differ ultrastructurally and histochemically from the amyloid of senile plaques. Neurosci Lett 1989; 105: 294-99.
65. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 2004; 12: 584-95.